SGLT2 Inhibitors: Town Hall Benefits vs Concerns: A renal perspective
|
|
- Winfred Glenn
- 5 years ago
- Views:
Transcription
1 SGLT2 Inhibitors: Town Hall Benefits vs Concerns: A renal perspective Matthew R. Weir, MD Professor and Chief Division of Nephrology University of Maryland School of Medicine
2 Disclosure Slide Scientific Advisor: Janssen, Astra, BI, MSD, Akebia, Relypsa, Boston Scientific, Lexicon Grant Funding: NIDDK: R01DK and U01DK106102, NHLBI: R01HL127422
3 Concerns: Ketoacidosis Reduction in egfr
4 Case Presentation: History 54-year-old African American female Type 2 diabetes mellitus x 8 years Hypertension x 12 years Nonsmoker Past history Obesity OA of the knees Current medications Insulin, pioglitazone Atorvastatin 20 mg once daily HCTZ 25 mg QD, metoprolol 25 mg BID
5 Case Presentation: Physical Exam BP 154/92 mm Hg PR 68 Weight 106 kg BMI 36.6 kg/m 2 Retinopathy, S4, 1+ edema Diminished peripheral pulses Peripheral neuropathy egfr = estimated glomerular filtration rate; FBG = fasting blood glucose; FLP = fasting lipid profile; HbA 1c = glycosylated hemoglobin; UAE = urinary albumin excretion; WNL = within normal limits.
6 Case Presentation: Lab Findings Scr 1.3 mg/dl, K 5.1 meq/l, A1 c 8.8% Estimated GFR = 56 ml/min/1.73 m 2 TG 220 mg/dl, HDL 33 mg/dl, LDL 98 mg/dl Urine Analysis: 1+ glucose, 3+ protein, no cells, casts, crystals 24 hour urine total protein 1,752 mg alb/cr ratio 1,550 mg/g sodium 287 meq Renal Sono: 11 cm kidneys, mild echogenicity
7 54-year-old African American Female with Hypertension, Type 2 Diabetes, Macroalbuminuria What is working diagnosis and differential? What additional laboratory data? What are the Treatment Options?
8 What are optimal treatment considerations? 1. BP below 130/80 mmhg 2. RAS inhibition 3. Tight control of hemoglobin A1C 4. Anti-platelet therapy 5. Full dose statin
9 Concerns: Ketoacidosis Reduction in egfr
10 Ketogenic Pathways The 2 principal ketone bodies, acetoacetate and beta-hydroxy butyrate are derived from the metabolism of FFA released from adipocytes and delivered to the liver FFA are activated to their acetyl CoA derivative The primary determinates as to whether acetyl CoA is directed toward a ketogenic or non-ketogenic pathway are the concentrations of insulin and glucagon
11 Malonyl CoA Increased production with high insulin, and low glucagon Increased malonyl CoA inhibits fatty acyl CoA entry into mitochondria Fatty acids are directed to TG Synthesis Under conditions of low insulin and high glucogon, malonyl CoA levels are reduced, facilitating entry of fatty acyl CoA into the mitochondria to form ketoacids
12 Starvation Ketosis More efficient renal conservation of ketone bodies through saturable and non-saturable pathways Increased production of ketone bodies suppresses protein catabolism by reducing the need for gluconeogenesis Ultimately, the rate of ketone body synthesis matches the rate of ketone body utilization There is usually a sufficient amount of insulin to prevent excessive mobilization of fatty acids, because ketone bodies stimulate insulin production
13 Starvation Ketosis Adaptive response Minimize loss of metabolic fuels Spares sodium and potassium losses Minimize loss of ammonium nitrogen Minimizes protein break down No net consumption of bicarbonate
14 Negative feedback loop on insulin secretion does not occur Greater fatty acid mobilization Unrestrained hepatic ketone body production Production of ketones exceeds utilization Increase in gluconeogenesis Diabetic Ketoacidosis Increased muscle breakdown and release of aminoacids Loss of urinary ketone bodies as sodium or potassium salts represents indirect loss of bicarbonate
15 SGLT 2 Inhibitor Ketoacidosis Reduction in glucose leads to a reduction in insulin (glucose is the chief stimulus for insulin release) Increase in plasma glucagon via 1) diminished inhibitory effect of insulin on glucagon release and 2) inhibition of the SGLT2 transporter in the pancreatic alpha cells (triggering glucagon release) Glucagon may directly suppress insulin release Degree of insulin deficiency and resistance induced by SGLT 2 inhibitors is much less than in DKA, so that glucose over production and underutilization is quantitively less, and often results in euglycemic ketoacidosis
16 SGLT2 Inhibitor Ketoacidosis delivery of FFA to the kidney oxidation of FFA leads to ATP consumption of ATP byna+ K+ -ATPase because of sodium cellular entry consumption and production of ATP causes a decrease of other ATP generating pathways This change causes a secondary reduction in other cellular pathways to generate ATP, such as renal ammoniagenesis from the metabolism of glutamine and the uptake and metabolism of filtered ketone bodies
17 SGLT2 Inhibitor Ketoacidosis The excretion of ketone bodies in the urine as either a Na+ or K+ salt represents a net bicarbonate loss However, if ketone bodies are excreted with NH4 +, there is no net change in the H + or HCO 3 concentration Ketonuria may increase and exceed the NH4 + excretion rate, resulting in the development of metabolic acidosis, especially in the setting of ATP excess and reduced ammoniagenesis
18 SGLT2 Inhibitor Ketoacidosis Since urinary excretion of ketoacid salts coupled to NH4 + is neutral with regard to acid-base balance it is critical to understand predisposing factors: CKD, diabetes, RAAS blockade, Type IV RTA, etc; since hyperkalemia suppresses renal ammoniagenesis Thus, decreased renal ATP consumption in the proximal tubule by SGLT2 inhibitors may lead to bicarbonate loss (with Na + or K + resulting in ketoacidosis
19 The role of the kidney in SGLT2-induced ketoacidosis. Palmer B. Journal of Diabetes and Its Complications 30 (2016)
20 Renal Handling of Ketones in Response to SGLT2 Inhibition in Patients with T2DM n=66 patients with T2DM, egfr >60ml/min 4 weeks of empaglifozin 25 mg daily Fractional excretion of glucose rose from 38 to 46% (fasting, postmeal) Excretion of beta-hydroxybutyrate, lactate, and sodium increased positively related to glycosuria Similar observations of lesser magnitude were seen in non-diabetic controls (n=25) It appears that SGLT2 inhibitor mediated ketoacidosis is due to increased production, rather than reduced renal clearance, as might be seen in starvation ketosis. Fernannini E, et al. Diabetes Care (In Press)
21 Ketone Bodies and Renal Function Ketone bodies enhance GFR and RPF which may counter the effect of TGF in reducing GFR via pre-glomerular vasoconstriction Stabilization of urinary Na+ losses may be helpful to limit ketone body excretion as a sodium salt which could worsen acidosis Ferraninni, E. et al. Diabetes Care (In Press)
22 Relationship between glucose excretion and urinary excretion of β- hydroxybutyrate during chronic treatment with empagliflozin Fernannini E, et al. Diabetes Care (In Press)
23 Relationship between glucose excretion and urinary excretion of lactate during chronic treatment with empagliflozin Fernannini E, et al. Diabetes Care (In Press)
24 Relationship between glucose excretion and urinary excretion of sodium during chronic treatment with empagliflozin Fernannini E, et al. Diabetes Care (In Press)
25 Urinary β hydroxybutyrate (β-hb and lactate excretion rate during fasting and following meal ingestion at baseline, after acute and chronic empagliflozin administration in patients with type 2 diabetes Fernannini E, et al. Diabetes Care (In Press)
26 Factors Which Could Predispose to Ketoacidosis Reduced egfr Hyperkalemia which reduces renal ammoniagenesis RAAS blockers Type 4 RTA Conditions which increase fatty acid delivery to the kidney NSAIDs
27 Case Presentation Empagliflozin 10 mg and Lisinopril 20 mg started Labs assessed 3 weeks later: Anion Gap 18 HgbA1C 7.6% Creat 1.6 UACR 892 mg/g, urine ketostix positive BP 136/82 mmhg
28 What would you do? Case Presentation ANION GAP CREATININE BP UACR
29 HgbA 1 C 7.1% with intensified insulin, pioglitazone and empalifozin BP 128/78 mmhg with increase in HCTZ 50 mg daily Creat stable at 1.6, and anion gap 12 Potassium 4.2 Case Presentation: 6 months later
30 Are SGLT2 inhibitors Renal and Cardio protective?
31 Possible Mechanisms of Benefit Glomerular Hyperfiltration Lower systemic blood pressure Lower glomerular capillary BP Pro-inflammatory Processes Lower BP, glucose, cholesterol Anti-inflammatory therapies? Enhance cellular energy via increased production of ATP
32 Glomerular Structure Mesangial Cell Capillary Loop Endothelial Cell Efferent Arteriole Afferent Arteriole Juxtaglomerular Apparatus
33 Renal glucose re-absorption under healthy conditions1,2 Filtered glucose load 180 g/day SGLT2 ~ 90% SGLT1 ~ 10% Virtually all of the filtered glucose is re-absorbed in the proximal In healthy tubules through individuals, SGLT2 and SGLT1 the with renal SGLT2 glomeruli accounting filter for ~ 90% ~180 in the g S1 and S2 of segments glucose per and SGLT1 accounting day for ~ 10% in the S3 segment SGLT, sodium glucose cotransporter. Adapted from: 1. Gerich JE. Diabet Med. 2010;27: ; 2. Bakris GL, et al. Kidney Int. 2009;75;
34 Renal glucose re-absorption in patients with diabetes1,2 Filtered glucose load > 180 g/day SGLT2 ~ 90% SGLT1 ~ 10% SGLT, sodium glucose cotransporter. Adapted from: 1. Gerich JE. Diabet Med. 2010;27: ; 2. Bakris GL, et al. Kidney Int. 2009;75; When blood glucose increases above the renal threshold (~ 11 mmol/l or 190 mg/dl), the capacity of the transporters is exceeded, resulting in urinary glucose excretion
35 Postulated tubuloglomerular feedback (TGF) mechanisms in normal physiology, early stages of diabetic nephropathy, and after sodium-glucose cotransporter (SGLT) 2 inhibition. David Z.I. Cherney et al. Circulation. 2014;129:
36 Postulated tubuloglomerular feedback (TGF) mechanisms in normal physiology, early stages of diabetic nephropathy, and after sodium-glucose co-transporter (SGLT) 2 inhibition. David Z.I. Cherney et al. Circulation. 2014;129:
37 Renal Hemodynamic Studies in T1DM 8 weeks of therapy with empagliflozin n=27 hyperfilterers (GFR >135 ml/min) and n=13 normal GFR Studied during euglycemic (4 6 mmol/l) and hyperglycemic (9 11 mmol/l) clamps at the beginning and end of 8 weeks treatment Cherney DZ et al. Circulation. 2014;129:
38 Glomerular filtration rate (GFR) responses to empagliflozin during clamped euglycemia (A) and hyperglycemia (B; mean±sd) *P<0.01 for baseline GFR in type 1 diabetes mellitus subjects without (T1D-N) vs with (T1D-H) renal hyperfiltration P<0.01 for the within-group change in GFR in T1D-H P<0.01 for the between-group effect of empagliflozin on change in GFR Cherney DZ et al. Circulation. 2014;129:
39 EMPA-REG Outcome Study 7020 patients with T2DM at high risk for CV events were randomized to receive placebo, empaglifozin 10 gm, or empaglifozin 25 mg once daily Median observation time 3.1 years Primary composite outcome measure: death from CV causes, nonfatal MI, or nonfatal stroke Zinman B, et al. NEJM 2015; 373:
40 Zinman B et al. N Engl J Med 2015;373: Glycated Hemoglobin Levels
41 Cardiovascular Outcomes and Death from Any Cause Zinman B et al. N Engl J Med 2015;373:
42 LEADER Study Patients with type 2 diabetes and high cardiovascular risk were assigned to receive either the glucagon-like peptide 1 analogue liraglutide or placebo. The rate of first occurrence of cardiovascular death, nonfatal MI, or nonfatal stroke was lower with liraglutide.
43 Marso SP et al. N Engl J Med 2016;375: Primary and Exploratory Outcomes
44 Conclusions In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo.
45 Considerations about Newer Therapies Besides Safety and Efficacy Complementary with RAAS blockers? Would you see the effect if SBP is 110 mmhg, 120 mmhg, 130 mmhg, or only at higher SBP? Persistency of effect after drug cessation? Is change in albuminuria an adequate surrogate measure, or do we need observable stabilization of estimated GFR? Low salt diet and thiazide diuretics have anti-proteinuric effects.
46 Multiple theories about renal and CV benefits with SGLT2 Inhibitors Is it more than simply pressure/volume reduction?
47 Physiologic mechanisms implicated in the cardiovascular and renal protection with SGLT2 inhibition Hiddo J.L. Heerspink et al. Circulation. 2016;134:
48 Raised circulating FFAs are taken up by the liver and metabolized via β-oxidation. Ele Ferrannini et al. Dia Care 2016;39:
49 However, if there is a reduction of GFR with the SGLT2 inhibitors; is this a good or adverse prognostic sign?
50 Relationship between 2-and 8-week changes in glomerular filtration rate (GFR) and subsequent renal and cardiovascular outcomes in 9340 patients new to RAS Blockade in ONTARGET/TRANSCEND Clase, et al. Kidney International (2017) 91,
51 Relationship between 2-and 8-week changes in glomerular filtration rate (GFR) and subsequent renal and cardiovascular outcomes in 9340 patients new to RAS Blockade in ONTARGET/TRANSCEND Clase, et al. Kidney International (2017) 91,
52 Association between percent decline in renal function in AASK and MDRD participants from time of randomization until month 3-4 and risk of ESRD Ku, Elaine (In Press)
53 Association between percent decline in renal function in AASK and MDRD participants from time of randomization until month 3-4 and risk of ESRD Ku, Elaine (In Press)
54 Which balance is required for CV and Renal Risk Reduction? PROTEINUIRA PRESSURE VOLUME EGFR
Managing patients with renal disease
Managing patients with renal disease Hiddo Lambers Heerspink, MD University Medical Centre Groningen, The Netherlands Asian Cardio Diabetes Forum April 23 24, 216 Kuala Lumpur, Malaysia Prevalent cases,
More informationSGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection
SGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection Hiddo Lambers Heerspink Department of Clinical Pharmacy and Pharmacology University Medical Center
More informationStages of Chronic Kidney Disease (CKD)
Early Treatment is the Key Stages of Chronic Kidney Disease (CKD) Stage Description GFR (ml/min/1.73 m 2 ) >90 1 Kidney damage with normal or GFR 2 Mild decrease in GFR 60-89 3 Moderate decrease in GFR
More informationMetabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationSUPPLEMENTARY DATA. Supplementary Table S1. Clinical characteristics of the study subjects.*
Supplementary Table S1. Clinical characteristics of the study subjects.* T2D ND n (F/M) 66 (21/45) 25 (7/18) Age (years) 61.8 ± 6.9 49.4 ± 7.3 # Body weight (kg) 95 ± 16 105 ± 13 # Body mass index (kg.
More informationDiabetic Nephropathy 2009
Diabetic Nephropathy 2009 Michael T McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetic Nephropathy Clinical Stages Hyperfunction
More informationTop HF Trials to Impact Your Practice
Top HF Trials to Impact Your Practice Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More informationDiabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker
Diabetes and New Meds for Cardiovascular Risk Reduction F. Dwight Chrisman, MD, FACC Disclosures: BI Boehringer Ingelheim speaker 1 Prevalence of DM DM state specific prevalence 2006 4%-6% 6-8% 8-10% 10-12%
More informationCKD FOR INTERNISTS. Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College
CKD FOR INTERNISTS Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College INTRODUCTION In 2002, the National Kidney Foundation s Kidney Disease Outcomes Quality Initiative(KDOQI)
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationSGLT2-inhibition: A New Strategy to Protect the Heart and the Kidney?
SGLT2-inhibition: A New Strategy to Protect the Heart and the Kidney? Hiddo Lambers Heerspink Department of Clinical Pharmacy and Pharmacology University Medical Center Groningen The Netherlands Disclosures:
More informationWhen Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes
When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes Kim K. Birtcher, MS, PharmD, AACC, FNLA, CLS, BCPS (AQ-Cardiology), CDE Clinical Professor University of Houston College
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationFaculty/Presenter Disclosure
CSI for CKD Unravelling the myths surrounding chronic kidney disease Practical Evidence for Informed Practice Oct 21 2016 Dr. Scott Klarenbach University of Alberta Slide 1: Option B (Presenter with NO
More informationDiabetic Nephropathy
Diabetic Nephropathy Objectives: Know what Diabetic Nephropathy means. Know how common is Diabetic nephropathy in Saudi Arabia and to appreciate how bad are this complications. Know the risk factors of
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationHave you seen a patient like Elaine *?
(linagliptin) 5mg tablets Have you seen a patient like Elaine *? *Hypothetical patient profile Elaine * : 60 years old Housewife *Hypothetical patient profile ELAINE*: T2D Patient with early signs of kidney
More informationSLOWING PROGRESSION OF KIDNEY DISEASE. Mark Rosenberg MD University of Minnesota
SLOWING PROGRESSION OF KIDNEY DISEASE Mark Rosenberg MD University of Minnesota OUTLINE 1. Epidemiology of progression 2. Therapy to slow progression a. Blood Pressure control b. Renin-angiotensin-aldosterone
More informationMorbidity & Mortality from Chronic Kidney Disease
Morbidity & Mortality from Chronic Kidney Disease Dr. Lam Man-Fai ( 林萬斐醫生 ) Honorary Clinical Assistant Professor MBBS, MRCP, FHKCP, FHKAM, PDipID (HK), FRCP (Edin, Glasg) Hong Kong Renal Registry Report
More informationPROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI. Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona
PROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona Disclosure Dr Massimo Boemi has been granted as speaker
More informationPhysio 12 -Summer 02 - Renal Physiology - Page 1
Physiology 12 Kidney and Fluid regulation Guyton Ch 20, 21,22,23 Roles of the Kidney Regulation of body fluid osmolarity and electrolytes Regulation of acid-base balance (ph) Excretion of natural wastes
More informationPredicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
More informationManaging Chronic Kidney Disease: Reducing Risk for CKD Progression
Managing Chronic Kidney Disease: Reducing Risk for CKD Progression Arasu Gopinath, MD Clinical Nephrologist, Medical Director, Jordan Landing Dialysis Center Objectives: Identify the most important risks
More informationFiltration and Reabsorption Amount Filter/d
Renal Physiology 2011 Lisa M. Harrison-Bernard, PhD Contact me at lharris@lsuhsc.edu Renal Physiology Lecture 3 Renal Clearance and Glomerular Filtration Filtration and Reabsorption Amount Filter/d Amount
More informationThe kidney. (Pseudo) Practical questions. The kidneys are all about keeping the body s homeostasis. for questions Ella
The kidney (Pseudo) Practical questions for questions Ella (striemit@gmail.com) The kidneys are all about keeping the body s homeostasis Ingestion Product of metabolism H 2 O Ca ++ Cl - K + Na + H 2 O
More informationClinical Pearls in Renal Medicine
Clinical Pearls in Renal Medicine Joel A. Gordon MD Professor of Medicine Nephrology Division Staff Physician Kidney Disease and Blood Pressure Clinic Disclosures None of my financial holdings will have
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationSupplementary Online Content
Supplementary Online Content Afkarian M, Zelnick L, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. doi:10.1001/jama.2016.10924 emethods efigure
More informationJoslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function
Scenario 2: Reduced Renal Function 62 y.o. white man with type 2 diabetes for 18 years Hypertension and hypercholesterolemia Known proliferative retinopathy Current medications: Metformin 1000 mg bid Glyburide
More informationLECTURE 25: FILTRATION AND CLEARANCE NEPHRON FILTRATION
LECTURE 25: FILTRATION AND CLEARANCE NEPHRON FILTRATION 1. Everything in the plasma is filtered except large proteins and red blood cells. The filtrate in Bowman s capsule is an isosmotic fluid that is
More informationUpdates in Diabetes and Cardiovascular Disease Management: Are You Making the Link?
Updates in Diabetes and Cardiovascular Disease Management: Are You Making the Link? Denise Kolanczyk, PharmD, BCPS AQ Cardiology 1 Erika Hellenbart, PharmD, BCPS 2 Jennifer D Souza, PharmD, CDE, BC ADM
More informationBASELINE CHARACTERISTICS OF THE STUDY POPULATION
Study Summary DAILY ORAL SODIUM BICARBONATE PRESERVES GLOMERULAR FILTRATION RATE BY SLOWING ITS DECLINE IN EARLY HYPERTENSIVE NEPHROPATHY This was a 5-year, single-center, prospective, randomized, placebo-controlled,
More informationRenal physiology D.HAMMOUDI.MD
Renal physiology D.HAMMOUDI.MD Functions Regulating blood ionic composition Regulating blood ph Regulating blood volume Regulating blood pressure Produce calcitrol and erythropoietin Regulating blood glucose
More information6/10/2014. Chronic Kidney Disease - General management and standard of care. Management of CKD according to stage (KDOQI 2002)
Chronic Kidney Disease - General management and standard of care Dr Nathalie Demoulin, Prof Michel Jadoul Cliniques universitaires Saint-Luc Université Catholique de Louvain What should and can be done
More informationDiabetic Nephropathy. Objectives:
There are, in truth, no specialties in medicine, since to know fully many of the most important diseases a man must be familiar with their manifestations in many organs. William Osler 1894. Objectives:
More informationObjectives. Kidney Complications With Diabetes. Case 10/21/2015
Objectives Kidney Complications With Diabetes Brian Boerner, MD Diabetes, Endocrinology, and Metabolism University of Nebraska Medical Center Review screening for, and management of, albuminuria Review
More informationRENAL PHYSIOLOGY. Physiology Unit 4
RENAL PHYSIOLOGY Physiology Unit 4 Renal Functions Primary Function is to regulate the chemistry of plasma through urine formation Additional Functions Regulate concentration of waste products Regulate
More informationOutpatient Management of Chronic Kidney Disease for the Internist
Outpatient Management of Chronic Kidney Disease for the Internist Annual Meeting of Maryland Chapter of the American College of Physicians February 3, 2018 MARY (TESSIE) BEHRENS, MD, FACP, FASN, FNKF MID-ATLANTIC
More informationDrug Class Monograph
Drug Class Monograph Class: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drugs: Farxiga (dapagliflozin), Invokamet (canagliflozin/metformin), Invokana (canagliflozin), Jardiance (empagliflozin),
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationPaolo Fornengo SCDU Medicina Interna 3 AOU Città della Salute e della Scienza di Torino
Paolo Fornengo SCDU Medicina Interna 3 AOU Città della Salute e della Scienza di Torino The KID-ney behind the curtain Altered Renal Glucose Control in Diabetes Gluconeogenesis is increased in postprandial
More informationSodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes
Editorial Page 1 of 5 Sodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes Hidekatsu Yanai Department of Internal Medicine, National Center for Global Health and Medicine
More informationInvokana (canagliflozin) NEW INDICATION REVIEW
Invokana (canagliflozin) NEW INDICATION REVIEW Introduction Brand name: Invokana Generic name: Canagliflozin Pharmacological class: Sodium-glucose cotransporter 2 (SGLT2) inhibitor Strength and Formulation:
More informationElevation of Serum Creatinine: When to Screen, When to Refer. Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC
Elevation of Serum Creatinine: When to Screen, When to Refer Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC Presented at the University of Calgary s CME and Professional Development 2006-2007
More informationCollin College. BIOL Anatomy & Physiology. Urinary System. Summary of Glomerular Filtrate
Collin College BIOL. 2402 Anatomy & Physiology Urinary System 1 Summary of Glomerular Filtrate Glomerular filtration produces fluid similar to plasma without proteins GFR ~ 125 ml per min If nothing else
More informationFaculty. Disclosures. Learning Objectives. Definitions. Definitions (cont) The Role of the Kidney in Cardiometabolic Disease
Faculty The Role of the Kidney in Cardiometabolic Disease Christian W. Mende, MD, FACP, FACN, FASN, FASH Clinical Professor of Medicine University of California at San Diego San Diego, California Disclosures
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationPhysiology questions review
Physiology questions review 1- The consumption of O2 by the kidney: a- decrease as blood flow increases b- regulated by erythropoiten c- remains constant as blood flow increase d- direct reflects the level
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More informationKidney Disease, Hypertension and Cardiovascular Risk
1 Kidney Disease, Hypertension and Cardiovascular Risk George Bakris, MD, FAHA, FASN Professor of Medicine Director, Hypertensive Diseases Unit The University of Chicago-Pritzker School of Medicine Chicago,
More informationDr Brandon Orr-Walker
Dr Brandon Orr-Walker Endocrinologist Clinical Head of Endocrinology and Diabetes Middlemore Auckland 17:45-18:10 What Can New Agents Offer Us? Diabetes Management What do the new agents offer us? Brandon
More informationThe EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada
The EMPA-REG OUTCOME trial: Design and results David Fitchett, MD University of Toronto, Canada Asian Cardio Diabetes Forum April 23 24, 2016 Kuala Lumpur, Malaysia Life Expectancy Is Reduced by ~12 Years
More informationCopyright 2009 Pearson Education, Inc. Copyright 2009 Pearson Education, Inc. Figure 19-1c. Efferent arteriole. Juxtaglomerular apparatus
/6/0 About this Chapter Functions of the Kidneys Anatomy of the urinary system Overview of kidney function Secretion Micturition Regulation of extracellular fluid volume and blood pressure Regulation of
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationHave you seen a patient like Carol *?
(linagliptin) 5mg tablets Have you seen a patient like Carol *? *Hypothetical patient profile Carol * : 70 years old Retired schoolteacher *Hypothetical patient profile CAROL*: T2D patient with moderate
More informationCASE 27. What is the response of the kidney to metabolic acidosis? What is the response of the kidney to a respiratory alkalosis?
CASE 27 A 21-year-old man with insulin-dependent diabetes presents to the emergency center with mental status changes, nausea, vomiting, abdominal pain, and rapid respirations. On examination, the patient
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationRenal Quiz - June 22, 21001
Renal Quiz - June 22, 21001 1. The molecular weight of calcium is 40 and chloride is 36. How many milligrams of CaCl 2 is required to give 2 meq of calcium? a) 40 b) 72 c) 112 d) 224 2. The extracellular
More informationCARDIO-RENAL SYNDROME
CARDIO-RENAL SYNDROME Luis M Ruilope Athens, October 216 DISCLOSURES: ADVISOR/SPEAKER for Astra-Zeneca, Bayer, BMS, Daiichi-Sankyo, Esteve, GSK Janssen, Lacer, Medtronic, MSD, Novartis, Pfizer, Relypsa,
More informationVariability in drug response: towards more personalized diabetes care Petrykiv, Sergei
University of Groningen Variability in drug response: towards more personalized diabetes care Petrykiv, Sergei IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you
More informationDiabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Diabetes Oral Agents Pharmacology University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 Learning Objectives Understand the role of the utilization of free
More informationNEW DIABETES CARE MEDICATIONS
NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.
More informationDiabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin
Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Disclosures I have no financial relationship with the manufacturers of any commercial product discussed during this
More informationIrish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012
Irish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012 Susan McKenna Renal Clinical Nurse Specialist Cavan General Hospital Renal patient population ACUTE RENAL FAILURE
More informationHyperglycemia: Type I Diabetes Mellitus
296 PHYSIOLOGY CASES AND PROBLEMS Case 53 Hyperglycemia: Type I Diabetes Mellitus David Mandel was diagnosed with type I (insulin-dependent) diabetes mellitus when he was 12 years old (see Cases 30 and
More informationHYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL
HYPERTENSION IN CKD LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL Stages in Progression of Chronic Kidney Disease and Therapeutic Strategies Complications Normal Increased risk Damage GFR
More informationABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour
ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical
More informationAmerican Diabetes Association Standards of Medical Care in Diabetes 2017: Focus on Complications
American Diabetes Association Standards of Medical Care in Diabetes 2017: Focus on Complications Juan Pablo Frias, M.D., FACE President and CEO, National Research Institute, Los Angeles, CA Clinical Faculty,
More informationPotassium regulation. -Kidney is a major regulator for potassium Homeostasis.
Potassium regulation. -Kidney is a major regulator for potassium Homeostasis. Normal potassium intake, distribution, and output from the body. Effects of severe hyperkalemia Partial depolarization of cell
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationDiabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018
Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Points to Ponder ASCVD is the leading cause of morbidity
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More informationEndocrinologist Sweetgrass Endocrinology
Endocrinologist Sweetgrass Endocrinology Sanders, Cummings Ask Justice Department to Investigate Insulin Prices The Department of Justice and the FTC are asked to investigate whether Lilly, Novo Nordisk,
More informationRenal physiology II. Basic renal processes. Dr Alida Koorts BMS
Renal physiology II Basic renal processes Dr Alida Koorts BMS 7-12 012 319 2921 akoorts@medic.up.ac.za Basic renal processes 1. filtration 2. reabsorption 3. secretion Glomerular filtration The filtration
More informationAggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
http://www.kidney-international.org & 2013 International Society of Nephrology Aggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
More informationThe Flozins Quest for Clarity?
The Flozins Quest for Clarity? Choosing Wisely with Academic Detailing 2018 ARE THEY THE REAL DEAL Disclosure statements The Academic Detailing Service is operated by Dalhousie Continuing Professional
More informationIntroduction to the kidney: regulation of sodium & glucose. Dr Nick Ashton Senior Lecturer in Renal Physiology Faculty of Biology, Medicine & Health
Introduction to the kidney: regulation of sodium & glucose Dr Nick Ashton Senior Lecturer in Renal Physiology Faculty of Biology, Medicine & Health Objectives Overview of kidney structure & function Glomerular
More informationOral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
Oral Agents Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What would your ideal diabetes drug do? Effective in lowering HbA1c No hypoglycaemia No effect on weight/ weight
More informationA factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
More informationPrevention of complications: are we winning or losing the battle. Naveed Sattar Professor of Metabolic Medicine
Prevention of complications: are we winning or losing the battle Naveed Sattar Professor of Metabolic Medicine Duality of Interest Declaration Consultant or speaker for: Amgen, AstraZeneca, Boehringer
More information014 Chapter 14 Created: 9:25:14 PM CST
014 Chapter 14 Created: 9:25:14 PM CST Student: 1. Functions of the kidneys include A. the regulation of body salt and water balance. B. hydrogen ion homeostasis. C. the regulation of blood glucose concentration.
More informationFunctional morphology of kidneys Clearance
Functional morphology of kidneys Clearance Assoc. Prof. MUDr. Markéta Bébarová, Ph.D. Department of Physiology Faculty of Medicine, Masaryk University This presentation includes only the most important
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationBASELINE CHARACTERISTICS OF THE STUDY POPULATION
COMPARISON OF TREATING METABOLIC ACIDOSIS IN CKD STAGE 4 HYPERTENSIVE KIDNEY DISEASE WITH FRUITS & VEGETABLES OR SODIUM BICARBONATE This was a 1-year, single-center, prospective, randomized, interventional
More informationRenal Physiology - Lectures
Renal Physiology - Lectures Physiology of Body Fluids PROBLEM SET, RESEARCH ARTICLE Structure & Function of the Kidneys Renal Clearance & Glomerular Filtration PROBLEM SET Regulation of Renal Blood Flow
More informationGuest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2
Public Health Live T 2 B 2 Chronic Kidney Disease in Diabetes: Early Identification and Intervention Guest Speaker Joseph Vassalotti, MD, FASN Chief Medical Officer National Kidney Foundation Thanks to
More informationKetoacidosis with SGLT-2 Inhibitor and Ketogenic Diet: A Case Study
Ketoacidosis with SGLT-2 Inhibitor and Ketogenic Diet: A Case Study Mercedez D. Bernard D.O., Karen L. Schafer, D.O. Comanche County Memorial Hospital Abstract This case study illustrates the importance
More information2019 Update on Recent Guideline Releases for Diabetes, Hypertension, and Dyslipidemia: Can We, Please, All Just Get on the Same Page?!
2019 Update on Recent Guideline Releases for Diabetes, Hypertension, and Dyslipidemia: Can We, Please, All Just Get on the Same Page?! Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM Assistant Professor,
More informationHot Topics in Diabetic Kidney Disease a primary care perspective
Hot Topics in Diabetic Kidney Disease a primary care perspective DR SARAH DAVIES GP PARTNER WITH SPECIAL INTEREST IN DIABETES, CARDIFF DUK CLINICAL CHAMPION NB MEDICAL HOT TOPICS PRESENTER AND DIABETES
More informationRENAL PHYSIOLOGY WESTMEAD PRIMARY EXAM
RENAL PHYSIOLOGY WESTMEAD PRIMARY EXAM RENAL PHYSIOLOGY - ANATOMY Glomerulus + renal tubule Each kidney has 1.3 million nephrons Cortical nephrons (85%) have shorter Loop of Henle than Juxtamedullary nephrons
More informationApplication of the Diabetes Algorithm to a Patient
Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent
More informationJo Abraham MD Division of Nephrology University of Utah
Jo Abraham MD Division of Nephrology University of Utah 1. To highlight the link between AKI and progression to CKD 2. To discuss the newer agents that have come available for the treatment of hyperkalemia
More informationThe ABCs (A1C, BP and Cholesterol) of Diabetes
The ABCs (A1C, BP and Cholesterol) of Diabetes Gregg Simonson, PhD Director, Professional Training and Consulting International Diabetes Center; Adjunct Assistant Professor, University of Minnesota Department
More informationCan Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure?
UCSD Hawaii 2017 Symposium Can Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure? Gregg C. Fonarow, MD, FACC, FAHA Elliot Corday Professor of Cardiovascular Medicine UCLA Division of Cardiology
More informationErtugliflozin (Steglatro ) 5 mg daily. May increase to 15 mg daily. Take in the morning +/- food. < 60: Do not initiate; discontinue therapy
Sodium-glucose Cotransporter-2 (SGLT2) s Inhibit SGLT in proximal renal tubules, reducing reabsorption of filtered glucose from tubular lumen Lowers renal threshold for glucose à increase urinary excretion
More information